Assessment of the effects of telmisalthan and olmethaltan on inflammation and oxidative stress in patients on maintenance hemodialysis.

Trial Profile

Assessment of the effects of telmisalthan and olmethaltan on inflammation and oxidative stress in patients on maintenance hemodialysis.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2012

At a glance

  • Drugs Olmesartan medoxomil (Primary) ; Telmisartan (Primary)
  • Indications Secondary hypertension
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 01 Feb 2012 Results published in Clinical and Experimental Hypertension (CEH).
    • 25 Jan 2010 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 25 Jan 2010 Actual initiation date (Jan 2010) added as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top